nitric oxide · Vero Biotech Inc · NDA 202860
Genosyl
Earliest generic entry, as listed
22 Jul 2040
Blocked by patent: US 11672938. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.
Listed patents · 11 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11672938 | use U-3037 | 22 Jul 2040 |
| US 10213572 | product | 12 Feb 2036 |
| US 10737051 | product | 20 Oct 2035 |
| US 8607785 | product | 14 Jul 2030 |
| US 11103669 | product | 21 Jun 2030 |
| US 11511252 | product | 21 Sep 2029 |
| US 10926054 | product | 13 Aug 2029 |
| US 8944049 | product | 13 Aug 2029 |
| US 9604028 | use U-2793 | 13 Aug 2029 |
| US 9701538 | product | 28 Jan 2029 |
| US 7560076 | product | 21 Apr 2027 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 202860 · 001 · RLD | gas, inhalation | 800PPM | 22 Jul 2040 |
Expired or delisted (3)
- US 7618594 · product · 17 Oct 2026
- US 7947227 · use U-3037 · 17 Oct 2026
- US 8057742 · use U-3037 · 18 Jan 2026